The therapeutics pipeline of chronic kidney disease has been increasing on account of rising prevalence of diabetes and high blood pressure in patients. The diabetes and blood pressure are the main causes of chronic kidney disease, which is also related to cardiovascular disease. Due to altered lifestyle, the chances of incidence of high blood pressure and diabetes is on a rise. Currently, the prevalence of chronic kidney disease is around 14% in Australia, as studied by Oxford Academic Journal of Nephrology Dialysis Transplantation. According to, National Institute of Diabetes and Digestive and Kidney Disease, the number of kidney failure cases among the Americans stood at more than 661,000, out of which 468,000 patients are undergoing dialysis and 193,000 patients are living with functional kidney transplant. The increasing awareness of healthcare issues also contributes towards the of development of therapeutics pipeline for chronic kidney disease.
Chronic kidney disease is the condition that can lead to the damage of the kidneys. Some of the main symptoms of chronic kidney disease are, weight loss, insomnia, tiredness, blood in urine, feeling sick, muscle cramps shortness of breath.
Many companies are conducting clinical trials for the development of therapeutics for chronic kidney disease. Astellas Pharma, Inc., is in the process of introducing a drug by the name ASP1517, which is in Phase III stage of its clinical development. ASP1517 is an orally administered small molecule which is used for the treatment of anaemia associated with chronic kidney disease. AstraZeneca Plc is also introducing a drug named, Dapagliflozin, which is currently in its Phase III stage of clnical development. Dapagliflozin is a sodium-glucose cotransporter II inhibitor.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/chronic-kidney-disease-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of chronic kidney disease therapeutics include Astellas Pharma Inc., AstraZeneca Plc, Proteon Therapeutics, Inc., RegenMed (Cayman) Ltd, Gilead Sciences, Inc., GlaxoSmithKline Plc, Relypsa, Inc., Chugai Pharmaceutical, Inc., Kissei Pharmaceutical Co., Ltd, Boryung Pharmaceutical Co., Ltd.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)